News | June 26, 2018

Major Investments Expand Capacity And Services In Europe And Latin America

Source: Fisher Clinical Services
Contact The Supplier
Rheinfelden Architect Rendering
Rendering of Thermo Fisher Scientific's state-of-the-art pharma services supply chain facility in Rheinfelden, Germany. Construction expected to start in Q4 2018 for the 8,000 sq.meter facility.

To better serve a growing demand for global clinical supply services, worldwide, Thermo Fisher Scientific is investing $35 million in a state-of-the-art pharma services supply chain facility in Rheinfelden (Baden), Germany. Additionally, and in support of continued demand for services in Latin America, the company is investing $3 million to expand its current capacity and services in Buenos Aires, Argentina.

The Rheinfelden facility will leverage the latest technology and modern infrastructure to significantly increase European capacity for cold and ambient clinical trial materials in support of complex clinical research and so meet the growing needs of customers. The facility will be scalable for mixed-use space and provide a strategic logistical location for shipping either by road or air.

Construction is planned to start in Q4' 2018 for the 8,000 square meter facility at the 26,000 square meter site with an anticipated completion within 12 to 18 months. Once complete, this new facility will provide up to 200 new jobs locally. The investment includes the option for additional expansion with the potential for doubling the footprint.

In Latin America, Thermo Fisher Scientific is investing $3 million in a new Buenos Aires facility that replaces the current clinical trial materials distribution center. With a planned opening of Q1 2019, the new facility more than doubles the current ambient capacity and includes a nearly 400% increase in current cold chain capacity. Enhanced service offerings will include comparator sourcing as well as clinical ancillary materials supplies management.

The company's decision to expand is in response to a growing demand for Fisher Clinical Services global clinical supply services, worldwide. The new EU facility will also serve to address GDP guidelines, Clinical Trial Regulations Annex 6 and the new Falsified Medicines Directive 2019. These GMP/GDP facilities build on the company's existing footprint of 20 purpose-built cGMP facilities globally.

SOURCE: Fisher Clinical Services